



Our Mission


The Sortina's mission is to create a platform of life-saving world-class small molecule therapeutics targeting sortilin. Focusing on critical diseases such as cancer and neurodegenerative conditions where sortilin overexpression or dysfunction has been linked to disease progression.

In-house development of a first in class cancer drug, starting with Glioblastoma Multiforme, followed by consecutive inclusion of additional cancer forms and parallel optimization of unique small molecules for neurodegenerative diseases.

How to solve the cancer problem?

Target and eliminate cancer stem cells using a novel cancer drug principle in order to promote cure of cancer.

→ Prevent cancer infiltration, metastases as well as increase the efficiency of conventional therapies due to removal of treatment resistant cancer cells.



Chemotherapy kills most cancer cells

...but treatment resistant cancer stem cells remain

...and can seed a new tumor or spread and form metastasis



Unique Target and treatment strategy

Sortilin - a key player expanding the cancer stem cell population and is further highly expressed in many cancer forms and associated with aggressive disease with recurrences, metastases and cancer deaths.

STRATEGY - Oral administration of a small molecule inhibiting key functions of sortilin, thereby offering an optimal add on therapy revolutionizing cancer treatments. First indication Glioblastoma Multiforme.

Competitive advantage

- ✓ Strong IP covering a family of chemical structures
- ✓ First in class oral cancer treatment
- ✓ Patient friendly with favorable safety/tolerability profile
- ✓ Clear monotherapeutic effect and optimal as add on to conventional therapy with significant patient impact
- ✓ Cost-effective manufacturing
- ✓ Scalable, novel technology for many cancer types, neurodegenerative indications and beyond



Business plan


Develop series of optimal small molecules and formulations targeting Sortilin, creating a platform pipeline covering cancer, neurodegenerative indications and beyond.

Partnering after clinical proof of concept in Glioblastoma Multiforme, and other cancers. Potential partnering at earlier stage of brain-penetrant molecules for neurodegenerative indications.

Exit strategy for investors

Partnering agreement with pharmaceutical company after clinical PoC and likely earlier partnering deals for neurodegenerative indications.

With the capacity to reshape cancer treatments and target diseases linked to sortilin, our groundbreaking therapies possess transformative potential. This could lead to substantial deal terms, reaching multi-billion-dollar magnitudes and significant return of investment.



Investment opportunities

5M Euro in capital need to get ready for clinical evaluation with first indication Glioblastoma Multiforme.

- In a first tranche, we are seeking 750K Euro in equity:
 - ✓ To select candidate drug
 - ✓ Finalize pre-clinical efficacy and PK/PD package
 - ✓ Obtain Granted Orphan status

Team

- Spin out from University of Gothenburg - strong collaborations with academia and hospitals with access to state-of-the-art technology and preclinical models
- Highly experienced team with consultant experts in a variety of drug development areas

